Navigation Links
KV Pharmaceutical Company Completes New Board with Appointment of Former Johnson & Johnson Executive
Date:11/5/2013

ST. LOUIS, Nov. 5, 2013 /PRNewswire-USNewswire/ -- K-V Pharmaceutical Company ("KV") today announced the appointment of Janet Vergis to its Board of Directors.  Ms. Vergis currently serves as the Executive-In-Residence at Warburg Pincus, LLC.  Previously, she was the CEO of OraPharma, Inc. where she led the company's successful turnaround.  Prior to her role at OraPharma, Ms. Vergis managed a $6 billion portfolio at Johnson & Johnson as President of Janssen Pharmaceuticals, McNeil Pediatrics, and Ortho-McNeil Neurologics.  Ms. Vergis also contributed to a number of Johnson & Johnson companies during her career, serving as a member of company management boards for more than 10 years and holding positions of increasing responsibility in research and development, new product development, sales, and marketing.

"Janet has a proven track record with some of the leading pharmaceutical companies in the world," said Greg Divis, KV CEO.  "Her extensive knowledge and valuable insights will help guide us as our company continues to pursue helping women achieve healthier lives and healthier pregnancies."

"With more than 25 years of pharmaceutical leadership experience and longstanding success growing and developing businesses, Janet will be a tremendous asset to the KV Board and complements the skill sets of our other Board members," said Joseph M. Mahady, Chairman of the KV Board of Directors.

Janet Vergis is the final appointment to KV's new Board of Directors.  The company recently appointed former President of Wyeth Pharmaceuticals, Inc., Joseph Mahady, as its new Board Chair, and two Board members: Gregory Norden, former Senior Vice President and Chief Financial Officer for Wyeth Corporation, and James M. Goldfarb, MD, MBA, Director of Infertility Services of the University Hospitals of Cleveland Health Systems and Clinical Professor of Reproductive Biology at Case Western Reserve University (CWRU) School of Medicine. The recently-announced Directors join Joe McInnis, Managing Director of Greywolf Capital Management LP, Steve Nielson of Susquehanna International Group, and Greg Divis, President and Chief Executive Officer of KV Pharmaceutical on the Board to shape the company's role in advancing women's health as it builds upon its portfolio of FDA-approved medications.

About KV Pharmaceutical
K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare. The company is committed to advancing the health of women across the stages of their lives. For further information about K-V Pharmaceutical Company, please visit www.kvph.com.


'/>"/>
SOURCE K-V Pharmaceutical Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb 24, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Hemophilia Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Hemophilia market? ...
(Date:2/24/2017)... 24, 2017  In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to a ... internet on Tuesday, March 14, 2017 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
(Date:2/24/2017)... Feb. 23, 2017 The U.S. Food ... PhenoTest BC Kit, performed on the Pheno System. ... that cause bloodstream infections and provide information about ... to (antibiotic sensitivity). The test also reduces the ... important information, which can guide antibiotic treatment recommendations ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, ... June: From Not to Hot,” which will begin airing on February 24, 2017. The ... millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April ... diverse symposium on “Doping in Sport: How the Culture Might Change,” ... Hampton LLP. The symposium will be held at Pepperdine University in Malibu, California. ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an exciting, new, interactive publication where generations converge and explore the world from ... their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find ...
(Date:2/23/2017)... ... , ... Current Meditation , a new meditation concept ... U.S. starting this spring. Current Meditation focuses on “meditation for the modern world,” ... will be the first meditation concept in the U.S. offering franchising opportunities, setting ...
Breaking Medicine News(10 mins):